Search All Tech Briefings


Search technology briefings produced by NIHR Innovation Observatory. These are short reports on new or repurposed medicines that we have already sent to our stakeholders. Only those technologies (medicines) that are within the scope of our stakeholders will have a technology briefing available.  Search our technology briefings by intervention (drug or device), specific indication (disease or condition), or general therapeutic area.

| 150 Results

Title
Intervention Indication Therapeutic Area Year Actions
Navitoclax with ruxolitinib for myelofibrosis Navitoclax (ABT 263, ABT-263) , Ruxolitinib (Jakavi; INCB018424; CTP-543; ruxolitinib phosphate) Myelofibrosis Haematological Cancer and Lymphomas 2022 View  |  Download
Obecabtagene autoleucel for treating refractory or relapsed B cell acute lymphoblastic leukaemia Obecabtagene autoleucel Acute lymphoblastic leukaemia (ALL) Haematological Cancer and Lymphomas 2023 View  |  Download
Parsaclisib for marginal zone lymphoma – relapsed or refractory Parsaclisib (INCB050465) Marginal zone lymphoma (MZL) Haematological Cancer and Lymphomas 2021 View  |  Download
Pembrolizumab (Keytruda) for relapsed/refractory classical Hodgkin lymphoma Pembrolizumab (Keytruda; MK-3475) Hodgkin lymphoma Haematological Cancer and Lymphomas 2018 View  |  Download
Pembrolizumab for treatment of solid tumours – second line Pembrolizumab (Keytruda; MK-3475) Solid tumours Haematological Cancer and Lymphomas , Oncology 2021 View  |  Download
Pemigatinib for treating myeloproliferative neoplasms with FGFR1 rearrangement Pemigatinib (INCB054828) Myeloproliferative Neoplasms Haematological Cancer and Lymphomas 2022 View  |  Download
Pevonedistat in addition to azacitidine for Higher-Risk Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia and Low Blast Acute Myeloid Leukemia – first-line Azacitidine (Vidaza; CC-486) , Pevonedistat (MLN-4924; TAK-924) Acute myeloid leukaemia (AML) , Chronic myelomonocytic leukaemia (CMML) , Myelodysplastic syndrome (MDS) Haematological Cancer and Lymphomas 2020 View  |  Download
Phelinun for reduced intensity conditioning treatment prior to allogeneic haematopoietic stem cell transplantation Melphalan hydrochloride (Cydex; CDX-353; Phelinun) Acute myeloid leukaemia (AML) , Hodgkin lymphoma , Multiple myeloma (MM) , Neuroblastoma , Non-Hodgkin lymphoma (NHL) , Ovarian cancer Female Reproductive Cancer , Haematological Cancer and Lymphomas , Neurological Cancer 2021 View  |  Download
Pirtobrutinib for chronic lymphocytic leukaemia or small lymphocytic lymphoma after BTK inhibitor therapy Pirtobrutinib (LY3527727; LOXO-305) Chronic lymphocytic leukaemia (CLL) , Small lymphocytic lymphoma (SLL) Haematological Cancer and Lymphomas 2023 View  |  Download
Pirtobrutinib for mantle cell lymphoma Pirtobrutinib (LY3527727; LOXO-305) Mantle cell lymphoma Haematological Cancer and Lymphomas 2021 View  |  Download
Medicines
Medicine Industry's Gateway to NICE
Support for Industry
Outputs & Publications